Hansa Biopharma — Oktober 2025

[LP90]

Godmorgen

[LP90]

Godmorgen

[LP90]

Godmorgen

[LP90]

Godmorgen

[LP90]

Godmorgen

[exitnu]

God morgen

[exitnu]

Hansa Biopharma AB: Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler-Najjar syndrome who are immune to AAV

[exitnu]

Data from GNT-018-IDES trial supports feasibility of imlifidase as pretreatment in gene therapy treatment for patients with Crigler–Najjar syndrome who are immune to AAV | Hansa Biopharma

(www.hansabiopharma.com)

[exitnu]

Summa summarum: det validerer teknologien langt ud over den eksisterende nyretransplantationsindikation.

[Henrikhot]

Det bliver spændende hvordan salgstal ender q3 den 30 oktober. Tallene bliver afgørende for videre kursudvikling mod nord.

[LP90]

Godmorgen

[exitnu]

Hansa Biopharma; individuelle analytikerestimat:

Redeye: ca. 90-95 SEK (Q3 2025)​

Bryan Garnier: ca. 100-102 SEK (forår 2025)​

H.C. Wainwright: ca. 98-102 SEK (forår/sommer 2025)​

William Blair (kun interval): 90–143 SEK

[exitnu]

Triggere H2:

FDA BLA-ansøgning, Q3-rapport & konference, GBS fase 2 data & Strategic partner review (potentiale for nye partnere eller funding).

2,5 måneder med spændende nyheder

[Munchi]

ikke at forglemme GBM data i Q4

[exitnu]

Ja .. GBM data

[LP90]

Godmorgen

[LP90]

Exitnu /
Munchi tak for info

[exitnu]

God morgen

[exitnu]

Analyst Consensus på Hansa Biopharma's egen hjemmeside:

Analysts and consensus | Hansa Biopharma

We develop innovative immunomodulating therapies with the potential to transform the lives of people affected by rare immunologic conditions.

(www.hansabiopharma.com)

Price target (medianen): SEK 97 og med hele 6 købsanbefalinger (uden Redeye) ..

[LP90]

Godmorgen